212 related articles for article (PubMed ID: 22005783)
1. Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity.
Grkovic L; Baird K; Steinberg SM; Williams KM; Pulanic D; Cowen EW; Mitchell SA; Hakim FT; Martires KJ; Avila DN; Taylor TN; Salit RB; Rowley SD; Zhang D; Fowler DH; Bishop MR; Gress RE; Pavletic SZ
Leukemia; 2012 Apr; 26(4):633-43. PubMed ID: 22005783
[TBL] [Abstract][Full Text] [Related]
2. National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis.
Baird K; Steinberg SM; Grkovic L; Pulanic D; Cowen EW; Mitchell SA; Williams KM; Datiles MB; Bishop R; Bassim CW; Mays JW; Edwards D; Cole K; Avila DN; Taylor T; Urban A; Joe GO; Comis LE; Berger A; Stratton P; Zhang D; Shelhamer JH; Gea-Banacloche JC; Sportes C; Fowler DH; Gress RE; Pavletic SZ
Biol Blood Marrow Transplant; 2013 Apr; 19(4):632-9. PubMed ID: 23340040
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and cytokine biomarkers in patients with chronic graft-vs-host disease persisting seven or more years after diagnosis.
Goklemez S; Im AP; Cao L; Pirsl F; Steinberg SM; Curtis LM; Mitchell SA; Cowen EW; Baruffaldi J; Rose J; Mays J; Ostojic A; Holtzman NG; Hakim FT; Pavletic SZ
Am J Hematol; 2020 Apr; 95(4):387-394. PubMed ID: 31903638
[TBL] [Abstract][Full Text] [Related]
4. Predictors for Permanent Discontinuation of Systemic Immunosuppression in Severely Affected Chronic Graft-Versus-Host Disease Patients.
Curtis LM; Pirsl F; Steinberg SM; Mitchell SA; Baird K; Cowen EW; Mays J; Buxbaum NP; Pichard DC; Im A; Avila D; Taylor T; Fowler DH; Gress RE; Pavletic SZ
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1980-1988. PubMed ID: 28797782
[TBL] [Abstract][Full Text] [Related]
5. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D
Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907
[TBL] [Abstract][Full Text] [Related]
6. Significant Associations of IgG Glycan Structures With Chronic Graft-Versus-Host Disease Manifestations: Results of the Cross-Sectional NIH Cohort Study.
Prenc E; Pulanic D; Pucic-Bakovic M; Ugrina I; Desnica L; Milosevic M; Pirsl F; Mitchell S; Rose J; Vrhovac R; Nemet D; Lauc G; Pavletic SZ
Front Immunol; 2021; 12():633214. PubMed ID: 34335560
[TBL] [Abstract][Full Text] [Related]
7. Glycoprotein YKL-40: a novel biomarker of chronic graft-vs-host disease activity and severity?
Duraković N; Krečak I; Perić Z; Milošević M; Desnica L; Pulanić D; Pusic I; Kušec V; Vrhovac R; Pavletic SZ; Nemet D
Croat Med J; 2016 Jun; 57(3):239-46. PubMed ID: 27374825
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Cutaneous Disease Severity Estimates on Survival Outcomes in Patients With Chronic Graft-vs-Host Disease.
Baumrin E; Baker LX; Byrne M; Martin PJ; Flowers ME; Onstad L; El Jurdi N; Chen H; Beeghly-Fadiel A; Lee SJ; Tkaczyk ER
JAMA Dermatol; 2023 Apr; 159(4):393-402. PubMed ID: 36884224
[TBL] [Abstract][Full Text] [Related]
9. Oral chronic graft-vs.-host disease characterization using the NIH scale.
Fassil H; Bassim CW; Mays J; Edwards D; Baird K; Steinberg SM; Williams KM; Cowen EW; Mitchell SA; Hakim FT; Taylor T; Avila D; Zhang D; Grkovic L; Datiles M; Gress RE; Pavletic SZ
J Dent Res; 2012 Jul; 91(7 Suppl):45S-51S. PubMed ID: 22699667
[TBL] [Abstract][Full Text] [Related]
10. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
Saillard C; Crocchiolo R; Furst S; El-Cheikh J; Castagna L; Signori A; Oudin C; Faucher C; Lemarie C; Chabannon C; Granata A; Blaise D
Leuk Lymphoma; 2014 May; 55(5):1106-12. PubMed ID: 23822538
[TBL] [Abstract][Full Text] [Related]
11. Active thrombopoiesis is associated with worse severity and activity of chronic GVHD.
Bat T; Steinberg SM; Childs R; Calvo KR; Barrett AJ; Battiwalla M; Baird K; Zhang D; Pulanic D; Dunbar CE; Pavletic SZ
Bone Marrow Transplant; 2013 Nov; 48(12):1569-73. PubMed ID: 23832091
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of autoantibodies in a large cohort of patients with chronic graft-versus-host disease defined by NIH criteria.
Kuzmina Z; Gounden V; Curtis L; Avila D; Rnp TT; Baruffaldi J; Cowen EW; Naik HB; Hasni SA; Mays JW; Mitchell S; Baird K; Steinberg SM; Pavletic SZ
Am J Hematol; 2015 Feb; 90(2):114-9. PubMed ID: 25363867
[TBL] [Abstract][Full Text] [Related]
13. Validation of the human activity profile questionnaire in patients after allogeneic hematopoietic stem cell transplantation.
Herzberg PY; Heussner P; Mumm FH; Horak M; Hilgendorf I; von Harsdorf S; Hemmati P; Rieger K; Greinix H; Freund M; Lee SJ; Holler E; Wolff D
Biol Blood Marrow Transplant; 2010 Dec; 16(12):1707-17. PubMed ID: 20541028
[TBL] [Abstract][Full Text] [Related]
14. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915
[TBL] [Abstract][Full Text] [Related]
15. National Institutes of Health-Defined Chronic Graft-vs.-Host Disease in Pediatric Hematopoietic Stem Cell Transplantation Patients Correlates With Parameters of Long-Term Immune Reconstitution.
Lawitschka A; Gueclue ED; Januszko A; Körmöczi U; Rottal A; Fritsch G; Bauer D; Peters C; Greinix HT; Pickl WF; Kuzmina Z
Front Immunol; 2019; 10():1879. PubMed ID: 31507582
[TBL] [Abstract][Full Text] [Related]
16. Characterization of Hepatic Dysfunction in Subjects Diagnosed With Chronic GVHD by NIH Consensus Criteria.
Yang AH; Han MAT; Samala N; Rizvi BS; Marchalik R; Etzion O; Wright EC; Cao L; Hakim FT; Jones E; Kapuria D; Hickstein DD; Fowler D; Kanakry JA; Kanakry CG; Kleiner DE; Koh C; Pavletic SZ; Heller T
Transplant Cell Ther; 2022 Nov; 28(11):747.e1-747.e10. PubMed ID: 35878742
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria.
Sato T; Ichinohe T; Kanda J; Yamashita K; Kondo T; Ishikawa T; Uchiyama T; Takaori-Kondo A
Int J Hematol; 2011 Apr; 93(4):532-541. PubMed ID: 21465116
[TBL] [Abstract][Full Text] [Related]
18. Symptoms, Cytokines, and Quality of Life in Patients Diagnosed with Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation.
Lynch Kelly D; Lyon DE; Ameringer SA; Elswick RK
Oncol Nurs Forum; 2015 May; 42(3):265-75. PubMed ID: 25901378
[TBL] [Abstract][Full Text] [Related]
19. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study.
Grube M; Holler E; Weber D; Holler B; Herr W; Wolff D
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1781-1791. PubMed ID: 27343720
[TBL] [Abstract][Full Text] [Related]
20. CXCL9 Predicts Severity at the Onset of Chronic Graft-versus-host Disease.
Giesen N; Schwarzbich MA; Dischinger K; Becker N; Hummel M; Benner A; Radujkovic A; Müller-Tidow C; Dreger P; Luft T
Transplantation; 2020 Nov; 104(11):2354-2359. PubMed ID: 31929430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
